ISIS obtains United States patent.

ISIS Pharmaceuticals, Inc. (Carlsbad, CA) has patented antisense compounds, compositions and methods for modulating the expression of Jun N-terminal Kinase Kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun Nterminal Kinase Kinase-1. (US 6010906)